Evidence map›Paper›PMID 39356335›Full record

ArticleDie Ophthalmologie2024

[EndoArt®: results in patients with glaucoma drainage devices].

Johanna Wiedemann, Mert Mestanoglu, Anne Rekate, Caroline Gietzelt, Claus Cursiefen, Björn Bachmann

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Die Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Advances in corneal transplantation.Eye (London, England) · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johanna WiedemannZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland. johanna.wiedemann@uk-koeln.de.
Mert MestanogluZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.
Anne RekateZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.
Caroline GietzeltZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.
Claus CursiefenZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.
Björn BachmannZentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpenerstr. 62, 50937, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndoArt® (Eye Yon Medical, Ness Ziona, Israel) is a novel artificial corneal inner layer transplant and an innovative treatment alternative for patients at high risk for graft failure after posterior lamellar corneal transplantation (EK). AIM OF THE STUDY: We present the initial results of the EndoArt® implantation in patients with glaucoma drainage devices (GDD). PATIENTS AND SURGICAL PROCEDURE: In this study 12 eyes with GDD were retrospectively evaluated. All had a high risk of transplant rejection in cases of EK (previous other glaucoma surgery in addition to GDD, n = 8, condition following Descemet membrane endothelial keratoplasty, DMEK, n = 9, uveitis, n = 2, or synechiae, n = 2). The EndoArt® was secured with a gas bubble and one to three holding sutures. The preoperative and postoperative best spectacle-corrected visual acuity (BSCVA) and central corneal thickness (CCT) were determined. The need for additional gas injections (rebubbling) was analyzed.

resultsOctafluoropropane (C3F8) 12% was used in nine patients and sulfur hexafluoride (SF6) 20% in three patients as anterior chamber tamponade to ensure adhesion of the EndoArt®. At least one rebubbling was necessary in four eyes. The preoperative BSCVA was 1.6 (± 0.5) logMAR and significantly improved to 1.1 (± 0.6) logMAR after 12 weeks (p = 0.028). The preoperative CCT was 719 µm ± 145.7, which significantly decreased to 622.4 µm ± 174.9 after six weeks (p = 0.004) and to 591.7 µm ± 190.8 after 12 weeks (p = 0.096). In one eye, the prosthesis was explanted due to a suspected fibrotic remodelling of the cornea following multiple previous DMEKs. DISCUSSION: EndoArt® led to a significant improvement in BSCVA and reduction in CCT; however, there was a high rebubbling rate in patients with GDD. In high-risk patients, the use of EndoArt® may be advantageous in avoiding graft failure after EK.

Indexed as

GlaucomaGlaucoma Drainage ImplantsAdultAgedAged, 80 and overCorneal TransplantationEquipment Failure AnalysisFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeVisual AcuityCorneal transplantationEndoArt®Endothelial decompensationEndothelial keratoprosthesisKeratoplasty

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.